Literature DB >> 9147500

[Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection].

C Sánchez1, A Matamala, M Salavert, E Cuchí, M Pons, F Anglés, J Garau.   

Abstract

OBJECTIVE: To evaluate the efficacy and safety of cotrimoxazol plus rifampicin in staphylococcal osteoarticular infection.
METHOD: Open, non-comparative study of adult hospitalized patients with documented staphylococcal bone infection.
RESULTS: From Feb 1989 to Dec 1993 28 episodes of staphylococcal bone infection were treated in 14 men and 13 women; the mean age was 48 +/- 21 years (range, 11-84). They received cotrimoxazol (7 mg/kg/day of trimethoprim) plus rifampicin (600-1200 mg/day), both orally, every 8 to 12 h with a mean duration of treatment of 34.2 +/- 8.2 days (range, 21 to 55 days). This antibiotic regimen was initiated at the same time that appropriate surgery for each specific condition was undertaken. Diagnoses were postsurgical osteomyelitis (10 cases), infected total hip prostheses (4 cases, one with 2 episodes), osteomyelitis secondary to external pin fixation (5 cases), soft tissue infections linked to orthopedic implants (3 cases), two cases of metatarsal osteomyelitis (one diabetic foot and one patient with polineuropathy), and one case each of chronic osteomyelitis of femur, hematogenous lumbar spondylitis and posttraumatic osteomyelitis. Four patients had bacteremia. The duration of the infection, prior to surgery was less than one month in 12 episodes, 1 month to 2 years in 14, and in 2 cases, of 10 and 13 years, respectively. In 23 episodes the causal agent was Staphylococcus aureus and in 5 cases it was coagulase-negative staphylococci. Patients had received previous parenteral therapy with other antimicrobials during 2-40 days (X: 18.6 +/- 10.2 days). All patients but one had resolution of the infection and are currently asymptomatic 6 months to 5 years posttreatment in the 21 evaluable cases (X: 38 +/- 13.1 months). Five patients had adverse effects secondary to the antibiotic combination and in three these were severe enough to discontinue the antimicrobials. In no case of the 11 patients with post-treatment control cultures were staphylococci recovered from the wound.
CONCLUSIONS: The combination of cotrimoxazole plus rifampicin, both given orally, was highly effective in this selected group of patients. This combination should be considered as a useful alternative therapy of staphylococcal bone infection and deserves further study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9147500

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  4 in total

Review 1.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

Review 2.  Diagnosis and management of osteomyelitis. Decision analytic and pharmacoeconomic considerations.

Authors:  M Tavakoli; P Davey; B A Clift; H T Davies
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

3.  Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis.

Authors:  G Euba; O Murillo; N Fernández-Sabé; J Mascaró; J Cabo; A Pérez; F Tubau; R Verdaguer; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

4.  A multicenter randomized placebo controlled trial of rifampin to reduce pedal amputations for osteomyelitis in veterans with diabetes (VA INTREPID).

Authors:  Mary T Bessesen; Gheorghe Doros; Adam M Henrie; Kelly M Harrington; John A Hermos; Robert A Bonomo; Ryan E Ferguson; Grant D Huang; Sheldon T Brown
Journal:  BMC Infect Dis       Date:  2020-01-08       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.